70 related articles for article (PubMed ID: 37359444)
1. Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study.
Hsieh HH; Wu TY; Chen CH; Kuo YH; Hour MJ
Ther Adv Drug Saf; 2023; 14():20420986231181338. PubMed ID: 37359444
[TBL] [Abstract][Full Text] [Related]
2. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
[TBL] [Abstract][Full Text] [Related]
3. Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines.
Simmons C; Rayson D; Joy AA; Henning JW; Lemieux J; McArthur H; Card PB; Dent R; Brezden-Masley C
Ther Adv Med Oncol; 2022; 14():17588359211066677. PubMed ID: 35035535
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry.
Ibragimova KIE; Geurts SME; Laczkó D; Meegdes M; Erdkamp F; Heijns JB; Tol J; Vriens BEPJ; Aaldering KNA; Dercksen MW; Pepels MJAE; Peters NAJB; van de Winkel LMH; van de Wouw AJ; de Fallois A; van Kats MACE; Tjan-Heijnen VCG
Clin Breast Cancer; 2024 Feb; 24(2):103-111. PubMed ID: 38007349
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.
Palle J; Tougeron D; Pozet A; Soularue E; Artru P; Leroy F; Dubreuil O; Sarabi M; Williet N; Manfredi S; Martin-Babau J; Rebischung C; Abdelghani MB; Evesque L; Dreanic J; Hautefeuille V; Louafi S; Sefrioui D; Savinelli F; Mabro M; Rousseau B; Lecaille C; Bouché O; Louvet C; Lecomte T; Bonnetain F; Taieb J; Zaanan A
Oncotarget; 2017 Nov; 8(60):101383-101393. PubMed ID: 29254172
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients.
Lote H; Mousoullou F; Vlachogiannis G; Lampis A; Satchwell L; Peckitt C; Fong C; Begum R; Kidd S; Cromarty S; Gordon A; Fribbens C; Rao S; Starling N; Chau I; Cunningham D; Valeri N
Front Oncol; 2023; 13():1258365. PubMed ID: 38094609
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer.
Sardesai S; Sukumar J; Kassem M; Palettas M; Stephens J; Morgan E; Addison D; Baliga R; Stover DG; VanDeusen J; Williams N; Cherian M; Lustberg M; Wesolowski R; Ramaswamy B
Cardiooncology; 2020 Nov; 6(1):26. PubMed ID: 33292843
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer.
Fu X; Zhang Y; Yang J; Qi Y; Ming Y; Sun M; Shang Y; Yang Y; Zhu X; Gao Q
Onco Targets Ther; 2018; 11():6091-6100. PubMed ID: 30275713
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).
Mezzanotte-Sharpe J; ONeill A; Mayer IA; Arteaga CL; Yang XJ; Wagner LI; Cella D; Meropol NJ; Alpaugh RK; Saphner TJ; Swaney RE; Hoelzer KL; Gradishar WJ; Abramson VG; Sundaram PK; Jilani SZ; Perez EA; Lin NU; Jahanzeb M; Wolff AC; Sledge GW; Reid SA
Res Sq; 2024 Apr; ():. PubMed ID: 38746356
[TBL] [Abstract][Full Text] [Related]
10. Association between human epidermal growth factor receptor 2 status, namely low and zero expression, and prognosis in hormone receptor-positive breast cancer: a single-center retrospective study.
Hara Y; Yano H; Ishida Y; Iwasaki K; Yamaguchi R
Transl Cancer Res; 2024 Apr; 13(4):1773-1785. PubMed ID: 38737680
[TBL] [Abstract][Full Text] [Related]
11. Six Months vs. 12 Months of Adjuvant Trastuzumab Among Women With HER2-Positive Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Deng H; Du X; Wang L; Chen M
Front Oncol; 2020; 10():288. PubMed ID: 32266131
[No Abstract] [Full Text] [Related]
12. Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Connolly RM; Wang V; Hyman DM; Grivas P; Mitchell EP; Wright JJ; Sharon E; Gray RJ; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Wang J; Wisinski KB; Tricoli JV; Conley BA; Harris LN; Arteaga CL; O'Dwyer PJ; Chen AP; Flaherty KT
Clin Cancer Res; 2024 Apr; 30(7):1273-1280. PubMed ID: 38433347
[TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of CDK4/6 Inhibitors in De Novo or PR- or Very Elderly Post-Menopausal ER+/HER2- Advanced Breast Cancers.
Tang H; Yeo D; De Souza K; Ahmad O; Shafiq T; Ofor O; Anand A; Karim S; Khan S; Madhusudan S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958338
[TBL] [Abstract][Full Text] [Related]
14. Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer.
Yi Z; Rong G; Guan Y; Li J; Chang L; Li H; Liu B; Wang W; Guan X; Ouyang Q; Li L; Zhai J; Li C; Li L; Xia X; Yang L; Qian H; Yi X; Xu B; Ma F
NPJ Breast Cancer; 2020; 6():59. PubMed ID: 33145402
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.
Debien V; Agostinetto E; Bruzzone M; Ceppi M; Martins-Branco D; Molinelli C; Jacobs F; Nader-Marta G; Lambertini M; de Azambuja E
Clin Breast Cancer; 2024 Feb; ():. PubMed ID: 38514306
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB).
Ostwal V; Mandavkar S; Bhargava P; Srinivas S; Kapoor A; Shetty O; Kannan S; Chaugule D; Patil R; Parulekar M; Nashikkar C; Ankathi SK; Baheti AD; Mehta D; Kaushal RK; Yadav S; Shah A; Patkar S; Goel M; Ramaswamy A
J Clin Oncol; 2024 Mar; 42(7):800-807. PubMed ID: 37944079
[TBL] [Abstract][Full Text] [Related]
17. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).
Niikura N; Yamanaka T; Nomura H; Shiraishi K; Kusama H; Yamamoto M; Matsuura K; Inoue K; Takahara S; Kita S; Yamaguchi M; Aruga T; Shibata N; Shimomura A; Ozaki Y; Sakai S; Kiga Y; Izutani T; Shiosakai K; Tsurutani J
NPJ Breast Cancer; 2023 Oct; 9(1):82. PubMed ID: 37821514
[TBL] [Abstract][Full Text] [Related]
18. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer.
Celik A; Berg T; Jensen MB; Jakobsen E; Nielsen HM; Kümler I; Glavicic V; Jensen JD; Knoop A
Breast Cancer (Auckl); 2023; 17():11782234231203292. PubMed ID: 37810797
[TBL] [Abstract][Full Text] [Related]
19. Targeting
Dumbrava EEI; Balaji K; Raghav K; Hess K; Javle M; Blum-Murphy M; Ajani J; Kopetz S; Broaddus R; Routbort M; Demirhan M; Zheng X; Pant S; Tsimberidou AM; Subbiah V; Hong DS; Rodon J; Shaw KM; Piha-Paul SA; Meric-Bernstam F
JCO Precis Oncol; 2019; 3():. PubMed ID: 32923865
[TBL] [Abstract][Full Text] [Related]
20. Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis.
Cha C; Ahn SG; Yoo TK; Kim KM; Bae SJ; Yoon C; Park S; Sohn J; Jeong J
Breast Care (Basel); 2020 Aug; 15(4):408-414. PubMed ID: 32982652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
